POPULARITY
4 episodes with oligometastatic
4 episodes with oligometastatic
4 episodes with oligometastatic
4 episodes with oligometastatic
2 episodes with oligometastatic
2 episodes with oligometastatic
2 episodes with oligometastatic
2 episodes with oligometastatic
2 episodes with oligometastatic
Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]
Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]
Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]
Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]
Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]
As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies raise the question of newer technologies and how we apply this information to trials that already exist.Studies discussed in the episode:EMBARKSOLAR/SATURNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Tom D'Amico, professor and vice chairman of surgery and chief medical officer of the Duke Cancer Institute, about oligometastatic disease. They discuss the current updates of oligometastatic disease, The Society of Thoracic Surgeons (STS) guidelines on the surgical management of oligometastatic non-small cell lung cancer, and the importance of choosing the right patient. They also explore where the new boundaries of this procedure are, radiation therapy, and shared decision-making. Joel also highlights a surgical robot (spaceMIRA) at the International Space Station that completed its first surgery demo in zero gravity, the state of lung transplants in the United Kingdom, and the Priority Setting Partnership (PSP).  Joel also reviews recent JANS articles on perioperative extra corporeal membrane oxygenation in neonates with transposition of the great arteries, a randomized controlled trial on the effects of postoperative glucocorticoids on mitigation of organ dysfunction in patients with Type A aortic dissection, if socioeconomic factors impair uptake of neoadjuvant therapy for patients with locoregional esophageal cancer, and a nationwide analysis on malperfusion in patients with acute Type A aortic dissection. In addition, Joel explores a case report on a chest injury with an arrow penetrating the right lung with rent in the right atrium, an interview with Marko Turina, and an Onyx mechanical mitral valve replacement after previous mitral repair. Before closing, he highlights upcoming events in CT surgery.  JANS Items Mentioned 1.) Perioperative Extra Corporeal Membrane Oxygenation in Neonates With Transposition of the Great Arteries: 15 Years of Experience 2.) Effects of Postoperative Glucocorticoids on Mitigation of Organ Dysfunction in Patients With Type A Aortic Dissection: A Randomized Controlled Trial 3.) Do Socioeconomic Factors Impair Uptake of Neoadjuvant Therapy for Patients With Locoregional Oesophageal Cancer? 4.) Malperfusion in Patients with Acute Type A Aortic Dissection: A Nationwide Analysis CTSNET Content Mentioned 1.) Injury to the Chest With an Arrow Penetrating the Right Lung With Rent in the Right Atrium: A Case Report 2.) Giants in CT Surgery: An Interview With Marko Turina 3.) Redo Mitral Surgery: Onyx Mechanical Mitral Valve Replacement After Previous Mitral Repair  Other Items Mentioned 1.) The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer 2.) Surgery in Space: Tiny Remotely Operated Robot Completes First Simulated Procedure at the Space Station 3.) Career Center  4.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
As part of the 2024 Prostate Cancer Patient Conference, Drs. Julian Hong and Eric Small discuss oligometastatic prostate cancer and its management with radiation and systemic therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39766]
As part of the 2024 Prostate Cancer Patient Conference, Drs. Julian Hong and Eric Small discuss oligometastatic prostate cancer and its management with radiation and systemic therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39766]
As part of the 2024 Prostate Cancer Patient Conference, Drs. Julian Hong and Eric Small discuss oligometastatic prostate cancer and its management with radiation and systemic therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39766]
As part of the 2024 Prostate Cancer Patient Conference, Drs. Julian Hong and Eric Small discuss oligometastatic prostate cancer and its management with radiation and systemic therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39766]
As part of the 2024 Prostate Cancer Patient Conference, Drs. Julian Hong and Eric Small discuss oligometastatic prostate cancer and its management with radiation and systemic therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39766]
In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment alternatives with local therapy, focusing on radiation.
In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as surgery, radiation and cryoablation impact treatment of this complex form of lung cancer.
Episode two of the Radiation Therapy podcast series discusses treatment of Oligometastatic disease, re-irradiation and role of palliative radiation, utilization of SBRT, introduction to proton therapy and mitigation of radiation-associated toxicities. Host: Mian M. Shahzad, MD, PhD (Gynecologic Oncologist; H. Lee Moffitt Cancer Center)Guest Speaker: Michael Montejo, MD (Radiation oncologist; H. Lee Moffitt Cancer Center) Sound engineered and produced by Tanya Colomb on behalf of the Society of Gynecologic Oncology.
Practical Radiation Oncology associate editor Louis Potters, MD, of Northwell Health hosts a conversation on Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Two of the authors, Puneeth Iyengar MD, PhD of Memorial Sloan Kettering Cancer Center and Matthias Guckenberger MD of the University Hospital Zurich, along with patient advocate Jill Feldman discuss the framework for the treatment of oligo-mets of lung cancer.
Practical Radiation Oncology associate editor Louis Potters, MD, of Northwell Health hosts a conversation on Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Two of the authors, Puneeth Iyengar MD, PhD of Memorial Sloan Kettering Cancer Center and Matthias Guckenberger MD of the University Hospital Zurich, along with patient advocate Jill Feldman discuss the framework for the treatment of oligo-mets of lung cancer.
Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the Nautilus: "the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer."Links to studies discussed in this episode (subscription may be required):OLIVIA: https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035Falcone et al.: https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedTRIBE: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20ItalianFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
As part of the 2022 Prostate Cancer Patient Conference, Dr. Felix Feng discusses metastasis-directed therapy and SBRT for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38570]
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Jack West discusses immunotherapy in patients who have oligometastatic disease.
Dr Akila Viswanathan talks with Dr Robert Timmerman from UT Southwestern about radiation therapy for oligometastatic disease as part of our series for Seminars in Radiation Oncology.
What do we need to know about the ablation of oligometastatic disease? Dr. Steven J. Chmura shares his vantage point on this topic and others from the 2021 San Antonio Breast Cancer Symposium.
We sit down with David Palma at ASTRO 2021 to discuss hot topics, including ORATOR2, De-escalation in HPV-driven oropharyngeal cancer, Oligometastatic disease, and more! @QuadShotNews@SamuelMarcromMD@LauraDoverMD@ASTRO_org#ASTRO21
The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center present the 2021 Patient Conference on Prostate Cancer. This session: Felix Feng, MD, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 37269]
The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center present the 2021 Patient Conference on Prostate Cancer. This session: Felix Feng, MD, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 37269]
The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center present the 2021 Patient Conference on Prostate Cancer. This session: Felix Feng, MD, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 37269]
The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center present the 2021 Patient Conference on Prostate Cancer. This session: Felix Feng, MD, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 37269]
The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center present the 2021 Patient Conference on Prostate Cancer. This session: Felix Feng, MD, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 37269]
There is hope now for some men with prostate cancer that has spread outside of the prostate. A new consideration for therapy is emerging. In this episode, we introduce Oligometastatic Prostate Cancer, a clinical distinction that will be new to many podcast listeners. Dr. Leslie Ballas from USC is a radiation oncologist and prostate cancer expert, and she will walk you through it today. She will talk about targeting those lesions with radiation therapy, who may be potential candidates, and if there is any benefit to treating the prostate in those men, additionally. Be sure to listen in today to learn about Oligometastatic Prostate Cancer from Dr. Ballas. Dr. Leslie Ballas is an Associate Professor of Clinical Radiation Oncology at the University of Southern California Norris Cancer Hospital. She received her undergraduate degree from Cornell University in New York and her Medical Doctorate from the University of Michigan. She completed her internship in General Surgery at Weill-Cornell Medical Center and her residency in Radiation Oncology at Columbia Presbyterian Hospital in New York. After residency, Dr. Ballas spent time on the faculty at MD Anderson Cancer Center. Her research has focused on improving the quality of life for men with prostate cancer. She is involved in developing cancer treatment clinical trials for genitourinary cancers. She has brought multiple genitourinary cooperative studies to USC. Her clinical interests include advanced technology integration into cancer therapeutics, including image-guided radiation therapy, stereotactic body radiotherapy, and intensity-modulated radiotherapy. Dr. Ballas is also proficient at treating hematological malignancies, including leukemia, lymphoma, and multiple myeloma. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show highlights: What led Dr. Ballas down the path she has taken in her research, and with her clinical efforts. What the term Oligometastatic Prostate Cancer means. Dr. Ballas talks about a recent driver for better discovering Oligometastatic lesions. What the consideration is for appropriate candidates in the development of more therapeutic strategies for men with Oligometastatic Prostate Cancer. The rationale behind using therapy directed towards metastatic lesions. Dr. Ballas describes the technology that typically gets used for targeting the lesions. The safety aspect and potential side-effects of the technology used to target the lesions. The people considered appropriate candidates for targeted therapy for metastatic lesions. Dr. Ballas discusses the benefits of additional treatment of the prostate for the candidates for targeted therapy. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link here, on our podcast website)  Join our Facebook group Follow Dr. Pohlman on Twitter and Instagram Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content. You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.
Hosts Jack West and Charu Aggarwal speak with radiation oncology experts David Palma of the London Health Sciences Centre and Puneeth Iyengar of University of Texas-Southwestern about the functional definition and treatment of oligometastatic cancer.
Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer.
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
The state between localized cancer and wide-spread metastatic disease is termed oligometastatic. This presentation explores radiotherapy and the principles of treatment for oligometastasis. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 36506]
Does PR status matter?, Google/DeepMind AI, Immune related rash might be good, Oligometastatic definition, Does more pounds = more life?, To SOAP or not to SOAP - a question many will face in the near future. quadshotnews@gmail.com @QuadShotNews
In this ANZUP conference highlight, this year’s convenor David Pryor chats to Phuoc Tran, a radiation oncologist from John Hopkins, about his success with the Oriel trial of stereotactic radiation for patients with oligometastatic prostate cancer.
Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer
Dr. Ken Pienta from The Johns Hopkins Hospital explains all about metastatic prostate cancer and how it spreads or metastasizes. He Includes in his discussion how prostate cancer is staged, how cancer migrates from the prostate gland to distant sites that can then develop into tumors. In this discussion He clarifies the difference between local invasion and metastatic disease. He also talks about the current reality of our scanning technology, including the new Axumin and PSMA scans and how large, or how many cells, need to be present in a tumor in order for it to be visualized. Dr. Pienta describes the current treatment issues surrounding oligometastatic prostate cancer (just a few tumors in the pelvic area) as well as the role of the tumor micro-environment in supporting the metastatic process. He also shared two clinical trials, the TED1 and the TED2 Trials (Total Obliteration Disease Trials) which he is conducting for newly diagnosed men with five or less metastatic lesions. Support the show (https://www.cancerabcs.org/new-page-2/)
Dr. Greg Riely from MSKCC and Dr. Jack West review the changing role for plasma NGS and local ablation therapy (LAT) for oligometastic disease (OMD) or oligoprogressing advanced NSCLC in clinical practice.
Dr. Greg Riely from MSKCC and Dr. Jack West review the changing role for plasma NGS and local ablation therapy (LAT) for oligometastic disease (OMD) or oligoprogressing advanced NSCLC in clinical practice.
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.
Dr Niazi discusses prostate oligometastatic targeted therapy in castration resistant prostate cancer.
We talk to Dr Neil Desai, Assistant Professor at Southwestern Medical Center, University of Texas, about his recent study published in BJR on treating oligometastatic cancer with stereotactic ablative radiation therapy.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden Prof Naredi talks to ecancertv at ECC 2015 about the use of surgery in synchronous oligometastatic disease. In the interview he highlights that two to three decades ago it was rare that patients with metastatic disease would be referred for surgery. Today, however, patients who have multiple metastatic sites may still be considered candidates for surgery, particularly if the metastases are all in the same organ such as the liver or lung. Prof Naredi emphasizes the importance of the multidisciplinary team when treating patients with oligometastatic disease.
Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.
Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.
Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.
© 2020-2025 Ivy Podcast Discovery LLC
